-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Teclistamab-cqyv is a bispecific T-cell engager that binds to the CD3 receptor on the surface of T cells and #BCMA expressed on the surface of #multiplemyeloma cells resulting in T-cell activation, proinflammatory cytokine release, and cellular lysis: https://t.co/SzuNWplZVa https://t.co/58DjIYBOSh
-
-
Mashup Score: 1Heavily Pre-Treated Patients With MM Respond to Cilta-Cel CAR T-Cell Therapy | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination November 14, 2022 Patients with multiple myeloma (MM) who had received multiple prior therapies, including B-cell maturation antigen (BCMA)–targeting agents, and had progressive disease responded to treatment…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Patients with #MultipleMyeloma (#MM) who received multiple prior therapies, including #BCMA-targeting agents, and had progressive disease responded to treatment with cilta-cel, resulting in MRD negativity https://t.co/6BCF63ysR2
-
-
Mashup Score: 0Blenrep for multiple myeloma withdrawn from U.S. market - 1 year(s) ago
As requested by the U.S. Food and Drug Administration, the multiple myeloma drug blenrep is being taken off the market after disappointing results in a phase 3 trial.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Blenrep for #MultipleMyeloma withdrawn from U.S. market! 👉https://t.co/HoW7Twg25m @ZosiaChustecka @MDedgeHemOnc #BCMA https://t.co/2YBd2HFKyx
-
-
Mashup Score: 1Blenrep for Multiple Myeloma Withdrawn From US Market - 1 year(s) ago
The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.
Source: MedscapeCategories: Hem/Oncs, Latest HeadlinesTweet-
#BCMA #ADC belanatamab withdrawn from the US. P3 confirmatory trial DREAMM3 (belantamab vs. PomDex) for #RRMM showed no PFS advantage (HR, 1.03; 95% CI, 0.72 – 1.47). #FDA #AcceleratedApproval mechanism works as it should!!! https://t.co/6zAp0pXgj7 https://t.co/AjKeDDnH2L
-
-
Mashup Score: 0GPRC5D-Targeted CAR T Cells for Myeloma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine — GPRC5D-Targeted CAR T Cells for Myeloma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
#GPRC5D-Targeted #CART Cells for #Myeloma👇 https://t.co/IetcEK0ad4 @Sean_m_devlin @MSKCC_OncoNotes #BCMA https://t.co/gEdCLrRbMK
-
-
Mashup Score: 13High antigen density of BCMA: friend or foe to CAR T cells? - 2 year(s) ago
The therapeutic landscape of multiple myeloma (MM) has been rapidly evolving with the development of newer modalities such as chimeric antigen receptor T-cell (CAR-T) therapies. Currently, there are two CAR-T cell products approved by the U.S. Food and Drug Administration for MM, idecabtagene
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @mahrefat: High antigen density of BCMA: friend or foe to CAR T cells? https://t.co/IwSbfxptMy #mmsm #BCMA @MarcelaMaus
-
High antigen density of BCMA: friend or foe to CAR T cells? https://t.co/5rSJTCJoqa
-
-
Mashup Score: 0Ask Dr Durie: BCMA-Directed Therapies in Multiple Myeloma - 2 year(s) ago
Are you taking advantage of all the modalities for targeting B-cell maturation antigen (BCMA)? Dr Durie and Dr Martin discuss BCMA-directed therapy in multiple myeloma.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
âť“ Are you taking advantage of all the modalities for targeting B-cell maturation antigen? #BCMA #OncTwitter âś… Take this #CME: https://t.co/MQt7MMVlhl https://t.co/t9lGCQj7uZ
-
-
Mashup Score: 1
Downloadable slideset on advances in relapsed/refractory multiple myeloma, from ProCE, LLC in partnership with Clinical Care Options (CCO).
Source: www.clinicaloptions.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @leochicaybam: Comparison of BCMA-targeted bispecifics in multiple myeloma #BCMA #mmsm #bispecifics Source: https://t.co/Hiau3jflDg htt…
-
-
Mashup Score: 2Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma - 2 year(s) ago
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally d…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma: https://t.co/DZIH8kgwMH @BloodAdvances @ASH_hematology #myeloma #BCMA
-
Teclistamab-cqyv is a bispecific T-cell engager that binds to the CD3 receptor on the surface of T cells and #BCMA expressed on the surface of #multiplemyeloma cells resulting in T-cell activation, proinflammatory cytokine release, and cellular lysis: https://t.co/SzuNWplZVa https://t.co/Tv6lHEDuEc